Theratechnologies Inc. (NASDAQ:THTX - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of Theratechnologies in a note issued to investors on Friday, October 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of $0.04 per share for the year, up from their previous forecast of $0.02. The consensus estimate for Theratechnologies' current full-year earnings is ($0.02) per share.
Theratechnologies Stock Performance
Shares of NASDAQ:THTX traded down $0.01 during trading hours on Monday, reaching $1.25. The stock had a trading volume of 69,084 shares, compared to its average volume of 45,637. Theratechnologies has a 1 year low of $0.88 and a 1 year high of $2.58. The firm's 50 day moving average is $1.27 and its 200-day moving average is $1.33. The stock has a market capitalization of $57.31 million, a price-to-earnings ratio of -6.56 and a beta of 1.41.
Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its quarterly earnings data on Thursday, October 10th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The company had revenue of $22.60 million for the quarter. During the same period in the previous year, the company posted ($0.03) earnings per share.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Read More
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
